Biosimilars Match Biologic Originators in RA A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA. https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l

• https://bit.ly/442M909

BIOSIMILARS (93 in EU, 40 in US) are approaching a tipping point with 8 new adalimumab biosimilars in 2023. Humira sales are down ~26% in 2023. Biosimilar sales expected - $129 billion in next 5 yrs, with estimated savings of $181 billion https://t.co/HMOYaSaIBQ https://t.co/6jOujr4JXQ

• https://bit.ly/3Pn6w4a

Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/AP89MAIlJM https://t.co/YpfWFCLF1z

• https://bit.ly/3Jitu8F

Should we be reassured of JAK safety with new data? Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy. https://t.co/gxLJGHXwlm https://t.co/SgdGRJXBIi

• https://bit.ly/43IDWic

Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/DGczkgHtpZ https://t.co/TquFCuh4QG

• https://wb.md/3NyTuz7

Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/fA6gzta5rx https://t.co/mGdzTqjEr7

• https://bit.ly/3Nxfevw

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Check out our Poster Hall today! https://t.co/opulSMICUf https://t.co/XtWePsWQCt

• https://bit.ly/43Fk7bo

Assessment of Psoriatic Arthritis: A Global Perspective Drs. Antoni Chan, Nelly Ziade and Ihsane Hmamouchi discuss POS1542 presented at EULAR 2023 in Milan, Italy. https://t.co/qkhdNDn37k https://t.co/Ux4PCxRdn8

• https://bit.ly/42J4Q8e

Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome? Dr. Yuz Yusof reports on abstracts OP0143 and LB0003 presented at EULAR 2023 in Milan, Italy. https://t.co/TPcdJ2rIsP https://t.co/5WZizA0TU8

• https://bit.ly/42KiwzJ

What to do with all this JAKi safety real world data? Dr. David Liew reporting from EULAR 2023 in Milan, Italy. https://t.co/AgDBOxAUx6 https://t.co/iRZuT0g7vq

• https://bit.ly/42M112f

Why Depression Screening Should be Mandatory at Each Visit Depression is more widespread than ever in the US, according to a new study from Gallup, showing that 18% of adults are depressed– an increase in 7 percentage points since 2015. https://t.co/2u82MXIFvb https://t.co/ZpGi4TYdBL

• https://bit.ly/467ujei

High Mortality Rates with Depression in Rheumatoid Arthritis A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA). https://t.co/R2MB4bs0Hr https://t.co/rWIfHmBqr8

• https://bit.ly/3X9TSY4

Excessive alcohol intake associated with higher risks of 61 diseases in men, including liver cirrhosis, stroke, and several gastrointestinal cancers, gout, cataracts, some fractures, and gastric ulcer. https://t.co/WqMuHQ3Unn https://t.co/IU0SaRcswZ

• https://go.nature.com/443iAMc

519 pts in the Hand OSTeoArthritis in Secondary care (HOSTAS) cohort studied & 17% had prolonged morning stiffness (>60 min); mild in 30%, intermediate in 37%, severe in 18% and extreme in 4%. Assoc w/ more pain, worse function and QOL https://t.co/6LSir7nSae https://t.co/lhoxwpfuqD

• https://bit.ly/3qLpd7v